Phase I study of H5.020CMV.PDGF-β to treat venous leg ulcer disease

Molecular Therapy

Volumn 17, Issue 10, 2009, Pages 1822-1829

  Margolis, David J ^a   Morris, Lee M ^a   Papadopoulos, Maryte ^a   Weinberg, Linda ^a   Filip, Jennifer C ^a   Lang, Stephanie A ^a   Vaikunth, Sachin S ^a   Crombleholme, Timothy M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; COMPRESSION THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; ERYTHEMA; FEASIBILITY STUDY; FEMALE; FEVER; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION PAIN; INJECTION SITE CELLULITIS; LEG ULCER; MALE; PERIULCER INJECTION; PHASE 1 CLINICAL TRIAL; PROMOTER REGION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS DETECTION; VIRUS REPLICATION; WOUND HEALING; WOUND INFECTION;

ADENOVIRIDAE; ADULT; CYTOMEGALOVIRUS; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; LEG ULCER; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET-DERIVED GROWTH FACTOR; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; VARICOSE ULCER;

ANIMALIA;

EID: 70349880437     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.169     Document Type: Article

References (36)

1. Ruckley, CV (1997). Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 48: 67-69.
2. Bickers, DR, Lim, HW, Margolis, D, Weinstock, MA, Goodman, C, Faulkner, E et al. (2006). The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 55: 490-500.
3. Coon, WW, Willis, PW and Keller, JB (1973). Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 48: 839-846.
4. Hallbook, T (1988). Leg ulcer epidemiology. Acta Chir Scand 544 17-20.
5. Phillips, TJ (1994). Chronic cutaneous ulcers: Etiology and epidemiology. J Invest Dermatol 102: 38S-41S.
6. O'Meara, S, Tierney, J, Cullum, N, Bland, JM, Franks, PJ, Mole, T et al. (2009). A systematic review of compression treatment for venous leg ulcers. BMJ 3385: 1047-1063.
7. Skene, AI, Smith, JM, Doré, CJ, Charlett, A and Lewis, JD (1992). Venous leg ulcers: A prognostic index to predict time to healing. BMJ 305: 1119-1121.
8. Falanga, V, Margolis, D, Alvarez, O, Auletta, M, Maggiacomo, F, Altman, M et al. (1998). Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 134 293-300.
9. Clark RAF (1996). Wound repair: Overview and general considerations. In: Clark RAF (ed). The Molecular and Cellular Biology of Wound Repair 2 edn. Plenum: New York. pp. 3-50.
10. Martin, P (1997). Wound healing - aiming for perfect skin regeneration. Science 276: 75-81.
11. Danilenko, DM, Ring, BD, Tarpley, JE, Morris, B, Van, GY, Morawiecki, A et al. (1995). Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor. Am J Pathol 147: 1261-1277.
12. Pierce, GF and Mustoe, TA (1995). Pharmacologic enhancement of wound healing. Annu Rev Med 46: 467-481.
13. Pierce, GF, Tarpley, JE, Tseng, J, Bready, J, Chang, D, Kenney, WC et al. (1995). Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest 96 1336-1350.
14. Beer, HD, Longaker, MT and Werner, S (1997). Reduced expression of PDGF and PDGF receptors during impaired wound healing. J Invest Dermatol 109: 132-138.
15. Wieman, TJ, Smiell, JM and Su, Y (1998). Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 21: 822-827.
16. Falanga, V, Eaglstein, WH, Bucalo, B, Katz, MH, Harris, B and Carson, P (1992). Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 18: 604-606.
17. Crombleholme, TM (2000). Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 8: 460-472.
18. Liechty, KW, Sablich, TJ, Adzick, NS and Crombleholme, TM (1999). Recombinant adenoviral mediated gene transfer in ischemic impaired wound healing. Wound Repair Regen 7: 148-153.
19. Sylvester, KG, Nesbit, M, Radu, A, Herlyn, M, Adzick, NS and Crombleholme, TM (2000). Adenoviral-mediated gene transfer in wound healing: Acute inflammatory response in human skin in the SCID mouse model. Wound Repair Regen 8: 36-44.
20. Gruss, CJ, Satyamoorthy, K, Berking, C, Lininger, J, Nesbit, M, Schaider, H et al. (2003). Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. J Invest Dermatol 120: 683-692.
21. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds-developing Products for Treatment (2006). Food and Drug Administration. pp. 1-18.
22. Kantor J and Margolis DJ (2000). Expected healing rates for chronic wounds. Wounds 12: 155-158.
23. Gelfand, JM, Hoffstad, O and Margolis, DJ (2002). Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol 119 1420-1425.
24. Margolis, DJ, Allen-Taylor, L, Hoffstad, O and Berlin, JA (2004). The accuracy of venous leg ulcer prognostic models in a wound care system. Wound Repair Regen 12: 163-168.
25. Bartus, CL and Margolis, DJ (2004). Reducing the incidence of foot ulceration and amputation in diabetes. Curr Diab Rep 4: 413-418.
26. Falanga V, Fujitani RM, Diaz C, Hunter G, Jorizzo J, Lawrence PF et al. (1997). Systemic treatment of venous leg ulcers with high doses of pentoxifylline: Efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 7: 208-213.
27. Steed, DL (1995). Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 21: 71-78; discussion 79.
28. Humpert, PM, Bärtsch, U, Konrade, I, Hammes, HP, Morcos, M, Kasper, M et al. (2005). Locally applied mononuclear bone marrow cells restore angiogenesis and promote wound healing in a type 2 diabetic patient. Exp Clin Endocrinol Diabetes 113: 538-540.
29. Vasa, M, Fichtlscherer, S, Aicher, A, Adler, K, Urbich, C, Martin, H et al. (2001). Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-E7.
30. Lin, Y, Weisdorf, DJ, Solovey, A and Hebbel, RP (2000). Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105: 71-77.
31. Mizrak, D, Brittan, M and Alison, MR (2008). CD133: Molecule of the moment. J Pathol 214: 3-9.
32. Margolis, DJ, Cromblehome, T, Herlyn, M, Cross, P, Weinberg, L, Filip, J et al. (2004). Clinical protocol. Phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer: Trial A. Hum Gene Ther 15: 1003-1019.
33. Wilson, JM (2009). Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96: 151-157.
34. FDA ICH E9 (1998). E9 Statistical Principles for Clinical Trials. . September.
35. Herrick, SE, Sloan, P, McGurk, M, Freak, L, McCollum, CN and Ferguson, MW (1992). Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol 141: 1085-1095.
36. Nonradioactive In Situ Hybridization Application Manual. . Accessed 5 January 2009.